LONDON & SAN FRANCISCO, 18 September 2008 – ThinkPanmure LLC, the growth-focused US investment banking subsidiary of Panmure Gordon & Co, is pleased to announce that it has acted as exclusive financial adviser to nanomaterials group Oxonica plc (OXN.L) on a strategic agreement with US medical technology firm Becton, Dickinson & Co (BD). Under the deal, BD will acquire the patents for Oxonica’s Nanoplex™ technology. Group chief executive, Tim Linacre, said: “This transaction demonstrates the Panmure Gordon Group’s ability to leverage its UK and US expertise to deliver effective cross-border solutions for our clients. President and head of investment banking at ThinkPanmure, Deborah Quazzo, said: “Our London and San Francisco offices have worked together to match the intellectual property of a long-term UK client to US capital, resulting in an excellent outcome for both Oxonica and BD,” she said. Panmure Gordon & Co acts as financial adviser, nominated adviser and broker to Oxonica plc in the UK. Further information: US: Deborah Quazzo President & Head of Investment Banking, ThinkPanmure Tel: +1 312 201 3101 UK: Nathaniel Webb Global Communications Manager, Panmure Gordon Tel: +44 20 7614 8333 About the Panmure Gordon Group Founded in 1876, Panmure Gordon & Co (PMR.L) is a leading independent mid-cap investment bank. Encompassing its US franchise, the Group employs approximately 300 professionals across the US, the UK and Nyon, Switzerland, offering a blend of transatlantic financial services including research, sales and trading, wealth management and asset management.